Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01332656 · ClinicalTrials.gov registry record · Phase 2

Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel

A Phase 2 study of Ovarian Cancer Recurrent, sponsored by Sanofi.

Completed
Registry status
Phase 2
Development phase
154
Enrollment target
20
Study locations

NCT01332656 is a Phase 2 study of Ovarian Cancer Recurrent that has completed, run by Sanofi. The registered enrollment target is 154 participants, above the 99-participant average among 4 other Ovarian Cancer Recurrent trials with a reported enrollment target (56% higher). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01332656, a Phase 2 study of Ovarian Cancer Recurrent, has completed, sponsored by Sanofi.

COMPLETED
Registry status
Phase 2
Development phase
154 participants
Enrollment target
20
Study locations

Study Summary

Primary Objective: \- To demonstrate an improvement in Progression-Free Survival (PFS) for Ombrabulin versus placebo in patients with platinum-sensitive recurrent ovarian cancer (OC) treated with paclitaxel and carboplatin. Secondary Objectives: * To compare the overall survival (OS) between the 2 treatment arms * To compare the objective response rate (RR) between the 2 treatment arms

Conditions Studied

Ovarian Cancer Recurrent

Interventions

  • DRUG Carboplatin
  • DRUG Placebo
  • DRUG Paclitaxel
  • DRUG Ombrabulin (AVE8062)

Study Locations (20)

Other

  • Investigational Site Number 056002 - Haine-Saint-Paul
  • Investigational Site Number 056005 - Kortrijk
  • Investigational Site Number 056001 - Leuven
  • Investigational Site Number 056003 - Namur
  • Investigational Site Number 203003 - Nový Jičín
  • Investigational Site Number 203002 - Olomouc
  • Investigational Site Number 203001 - Prague
  • Investigational Site Number 203004 - Zlín
  • Investigational Site Number 250006 - Bordeaux
  • Investigational Site Number 250004 - Caen
  • Investigational Site Number 250001 - Lyon
  • Investigational Site Number 250002 - Paris
  • Investigational Site Number 250003 - Villejuif
  • Investigational Site Number 276001 - München
  • Investigational Site Number 380004 - Genova

California

  • Investigational Site Number 840007 - Burbank

Connecticut

  • Investigational Site Number 840001 - New Haven

Florida

  • Investigational Site Number 840202 - Fort Meyers

Georgia

  • Investigational Site Number 840009 - Atlanta

Massachusetts

  • Investigational Site Number 840002 - Boston

Trial Details

FieldValue
Enrollment Target 154 participants
Start Date 2011-05
Est. Completion 2014-07
Phase Phase 2

Sponsor

Sanofi

713 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01332656

The ClinicalTrials.gov registry entry for NCT01332656 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 99-participant average among 4 other Ovarian Cancer Recurrent trials with a reported enrollment target (56% higher). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Ovarian Cancer Recurrent appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.

NCT01332656 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, California, Connecticut.

Frequently Asked Questions

What is clinical trial NCT01332656 about?

NCT01332656 is a clinical study titled "Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel". Primary Objective: \- To demonstrate an improvement in Progression-Free Survival (PFS) for Ombrabulin versus placebo in patients with platinum-sensitive recurrent ovarian cancer (OC) treated with paclitaxel and carboplatin. Secondary Objectives: * To compare the overall survival (OS) between the ...

What is the current status of trial NCT01332656?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 154 participants. The study started on 2011-05. Estimated completion is 2014-07.

What conditions does trial NCT01332656 study?

This clinical trial studies the following conditions: Ovarian Cancer Recurrent.

What interventions are being tested in trial NCT01332656?

The interventions under investigation include: Carboplatin (DRUG), Placebo (DRUG), Paclitaxel (DRUG), Ombrabulin (AVE8062) (DRUG).

Who is sponsoring clinical trial NCT01332656?

This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01332656 being conducted?

This trial has 20 study locations across California, Connecticut, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ovarian Cancer Recurrent

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ovarian Cancer Recurrent

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.